alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 851–875 of 1,109 studies · tagged Digital Tools (page 35 of 45) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Comparison of Feature Selection Techniques in Machine Learning for Anatomical Brain MRI in Dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuroinformatics 2016-07-01

We present a comparative split-half resampling analysis of various data driven feature selection and classification methods for the whole brain voxel-based classification analysis of anatomical magnetic resonance images. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region

✓ Peer-reviewed alzhub usefulness score 38 out of 100. American journal of human genetics 1992-11-01

A large number of familial Alzheimer disease (FAD) kindreds were examined to determine whether mutations in the amyloid precursor protein (APP) gene could be responsible for the disease. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Evaluating Sociodemographic Bias in an Artificial Intelligence Algorithm to Detect Cognitive Impairment in Electronic Health Records

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2024-12-01

Our study highlights the potential of Decipher‐AI for screening undiagnosed cognitive impairment in primary care. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Precision prevention in exercise: Integrating OMICS biomarkers and artificial intelligence for injury risk assessment

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Advanced Exercise and Health Science 2025-10-04

Exercise injuries present a significant challenge in medicine and public health, impacting exercise performance, career longevity, and overall quality of life. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Muti-band Morlet mutual information functional connectivity for classifying Alzheimer's disease and frontotemporal dementia with a deep learning technique

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Computers in Biology and Medicine 2025-09-05

Accurate differentiation of Alzheimer's disease (AD), frontotemporal dementia (FTD), and healthy control (HC) is critical for early diagnosis and intervention of brain disorders. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Integrative and interpretable framework to unveil the neurophysiological fingerprint of Alzheimer’s disease and mild cognitive impairment: A machine learning-SHAP approach

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of Applied Biomedicine 2025-06-13

Dementia and mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) are neurological pathologies associated with disruptions in brain electromagnetic activity, typically studied using magnetoencephalography (MEG) and electroencephalography (EEG). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

An Artificial Intelligence-Driven Multimorbidity Framework Reveals a Shared Metabolic and Immune Core Across Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biomedicines 2026-02-16

Across AD, ALS, and FTD, a convergent multimorbidity architecture centered on a shared metabolic and immune core was identified, accompanied by prominent neurobehavioral processes and intermediate systems including gastrointestinal, endocrine, hematological, hepatic, and sensory pathways. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mapping knowledge landscapes and emerging trends in digital biomarkers for dementia in older adults: A scoping and bibliometric analysis

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Archives of Gerontology and Geriatrics Plus 2025-04-09

This paper presents a systematic bibliometric analysis of the research landscape at the intersection of Alzheimer's disease and gerontechnology, identifying key contributors, research hotspots, and emerging trends. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying syntactic biomarkers of cognitive impairment in Mandarin-speaking older adults by applying machine learning approaches across multiple speech tasks

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Aphasiology 2025-05-28

The use of linguistic biomarkers for detecting cognitive decline and early stages of dementia has demonstrated great potential due to its low-cost and non-invasive nature, especially towards a large aging population. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Artificial intelligence in atrial fibrillation – Timely diagnosis, risk assessment and personalized management

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Indian Pacing and Electrophysiology Journal 2026-01-27

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide and is associated with substantial morbidity and mortality, including stroke, systemic embolism, heart failure, and dementia. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

APP‐mediated intracellular signaling rescues sleep impairment and blood–brain barrier leakage in Alzheimer's disease mouse model

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2026-02-01

APP‐mediated signaling plays a key role in regulating sleep, maintaining BBB integrity, and preserving memory in AD. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Ιnnovative Health Promotion Strategies: A 6-Month Longitudinal Study on Computerized Cognitive Training for Older Adults with Minor Neurocognitive Disorders

✓ Peer-reviewed alzhub usefulness score 38 out of 100. European Journal of Investigation in Health Psychology and Education 2025-03-12

Minor neurocognitive disorders (NCDs) represent a transitional phase between normal cognitive aging and dementia, highlighting the importance of early interventions. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Label-free detection of β-amyloid peptides (Aβ40 and Aβ42): a colorimetric sensor array for plasma monitoring of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nanoscale 2018-04-01

Monitoring the ratio of 40- and 42-residue amyloid β peptides (i.e., Aβ40 and Aβ42) in human plasma is considered one of the hallmarks of detection of the early stage of Alzheimer's disease (AD). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Methodology for Establishing a Community-Wide Life Laboratory for Capturing Unobtrusive and Continuous Remote Activity and Health Data

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Journal of visualized experiments : JoVE 2018-07-27

An end-to-end suite of technologies has been established for the unobtrusive and continuous monitoring of health and activity changes occurring in the daily life of older adults over extended periods of time. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

From across this tag

10 of the 1,102 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed